3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Anxiety Disorders
4
Neoplasms
2
Depression
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Testicular Germ Cell Tumor
1
Sarcoma
1
Pulmonary Disease, Chronic Obstructive
1
Ovarian Neoplasms
1
Lung Diseases, Interstitial
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Dyspnea
1
Interventions
pembrolizumab
59
Cisplatin
45
Cetuximab
29
Radiotherapy
26
Carboplatin
24
Docetaxel
17
Paclitaxel
16
Nivolumab
16
Surveys and Questionnaires
15
Radiotherapy, Intensity-Modulated
13
Fluorouracil
12
Drug Therapy
12
Blood Specimen Collection
11
Standard of Care
8
tislelizumab
7
cemiplimab
6
atezolizumab
6
Radiation
6
Chemoradiotherapy
6
toripalimab
5
Cyclophosphamide
5
130-nm albumin-bound paclitaxel
5
nimotuzumab
4
fludarabine
4
durvalumab
4
dostarlimab
4
Surgical Procedures, Operative
4
Afatinib
4
palbociclib
3
niraparib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Head and Neck Neoplasms
×
Hypnosis
×
1 year
×
Clear all
NCT04671485
2025-07-24
HYMACO
Institut de Cancérologie de Lorraine
Phase NA
Completed
60 enrolled